Abstract
The Epidermal Growth Factor Receptor (EGFR) signaling has known effects in bone homeostasis by modulating proliferation and differentiation of osteoblasts, osteoclasts and bone marrow osteoprogenitor cells. Studies in EGFR-deficient mice or in mice treated with EGFR-inhibitors, showed impaired bone formation. Patients affected by metastatic non-small cell lung cancer (NSCLC) with sensitizing mutations of the EGFR gene (mEGFR) are treated with EGFR-specific tyrosine kinase inhibitors (EGFR-TKIs), obtaining long-term disease control and improvement of quality of life (QOL).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
